Pacific Biosciences Announces New Chief Financial Officer
September 14 2020 - 9:00AM
Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading
provider of high-quality sequencing of genomes, transcriptomes, and
epigenomes, today announced the appointment of Susan G. Kim as
Chief Financial Officer, effective as of September 28, 2020.
“I am delighted that Susan is joining the company
at a time where we have many opportunities to drive growth,” said
Christian Henry, recently appointed Chief Executive Officer of
Pacific Biosciences. “Susan’s deep experience in all aspects
of financial operations will help drive our execution. Susan is
also a highly capable leader who has managed growth at both large
and small organizations. She will be a welcome addition to our
management team.”
Ms. Kim stated, “I am honored to be working with
Christian and the entire Pacific Biosciences team to accelerate
growth and deliver value for all stakeholders.”
Ms. Kim brings twenty plus years of senior-level
finance and operations experience to Pacific Biosciences, having
most recently served as Chief Financial Officer for App Annie and
Katerra, both leading venture-backed technology companies. In these
roles, Susan was instrumental in driving revenue growth, scaling
finance and operations, and realizing synergies through strategic
acquisitions. Over the course of Ms. Kim’s career, she has held a
variety of leadership roles with global multi-billion dollar public
companies including KLA Corporation, Morgan Stanley, and Advanced
Micro Devices. Ms. Kim earned an M.B.A./Master of Engineering
Management from Kellogg School of Management at Northwestern
University and a B.S. in Chemical Engineering from Stanford
University. In 2019, Ms. Kim was recognized as one of the Most
Influential Women in Bay Area Business by the San Francisco
Business Times.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:
PACB) is empowering life scientists with highly accurate
long-read sequencing. The company’s innovative instruments
are based on Single Molecule, Real-Time (SMRT®)
Sequencing technology,
which delivers a comprehensive view of genomes,
transcriptomes, and epigenomes, enabling access to the
full spectrum of genetic variation in any organism. Cited in
thousands of peer-reviewed publications,
PacBio® sequencing systems are in use by scientists
around the world to drive discovery in human biomedical
research, plant and animal sciences, and microbiology.
Forward-Looking Statements
All statements in this press release that are not
historical are forward-looking statements, including, among other
things, statements relating to plans for growth and success,
the commencement of employment of a new Chief Financial
Officer, and other future events. You should not place undue
reliance on forward-looking statements because they involve known
and unknown risks, uncertainties, changes in circumstances and
other factors that are, in some cases, beyond Pacific Biosciences’
control and could cause actual results to differ materially from
the information expressed or implied by forward-looking statements
made in this press release. Factors that could materially affect
actual results can be found in Pacific Biosciences’ most recent
filings with the Securities and Exchange Commission, including
Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and
10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
ContactsInvestors: Trevin
Rard 650.521.8450 ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Sep 2023 to Sep 2024